Filing Flows › BridgeBio Pharma (BBIO) › Q4 2025
BridgeBio Pharma (BBIO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 24, 2026
BridgeBio Pharma (BBIO) reported revenue of $154M for the fourth quarter 2025 (Q4 2025), up 26-fold from a year earlier and +28% from the quarter before. Operating margin was -90.5%, net loss $195M (126.2% of revenue).
BridgeBio Pharma, Q4 2025: revenue $154M (26× year over year), operating margin -90.5%, net loss $195M, operating cash flow −$56.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $154M | +28% | 26× |
| Operating profit | −$140M | — | — |
| Net earnings | −$195M | — | — |
| Operating cash flow | −$56.4M | — | — |
What changed
Revenue was $154.2M in Q4 2025, up 2521% year over year and up 28% from the previous quarter. Net product revenue was the largest line at 95% of revenue.
Operating costs exceeded revenue by $139.6M, an operating margin of -90.5%. Total costs grew 27% against revenue growth of 2521%. The fastest-growing cost line was Cost of revenue (+289%). The quarter ended with a net loss of $194.6M, wider than the previous quarter's $184.9M loss. Minority interests bore $1.8M of it: to shareholders the quarter was a loss of $192.9M.
Operating cash flow was −$56.4M. Non-cash charges added back $1.4M of depreciation and amortization and $34.6M of share-based compensation. Working capital and other items added $102.1M. Capital expenditures of $33K exceeded it, leaving free cash flow of −$56.5M.
Questions
What was BridgeBio Pharma's revenue in the fourth quarter 2025?
BridgeBio Pharma (BBIO) reported revenue of $154M for the fourth quarter 2025 (Q4 2025), up 26-fold from a year earlier and +28% from the quarter before.
Was BridgeBio Pharma profitable in the fourth quarter 2025?
Operating loss was $140M (-90.5% of revenue) and net loss $195M.
Source: BridgeBio Pharma 10-K on SEC EDGAR.